Pyxis Oncology (PYXS) Gross Margin (2024 - 2025)
Pyxis Oncology (PYXS) reported Gross Margin of 78.37% for Q4 2025, down 21.63% quarter-over-quarter from 100.0% in Q2 2025.
Pyxis Oncology (PYXS) Gross Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of Gross Margin data on file, last reported at 78.37% in Q4 2025.
- Gross Margin for Q4 2025 came in at 78.37%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 82.77% (down 1429.0% YoY), and the FY2025 annual result was 82.77%, down 1429.0% from the prior year.
- Gross Margin declined to 78.37% in Q4 2025 per PYXS's latest filing, from 100.0% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q2 2025 and troughed at 78.37% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | 78.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 78.37% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2024 | 97.06% |